RecruitingNCT03621904
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Sponsor
Radboud University Medical Center
Enrollment
150 participants
Start Date
Oct 15, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 110 Years
Inclusion Criteria4
- Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
- All histologic types of endometrial carcinoma
- Planned treatment with any type of hormonal therapy
- Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.
Exclusion Criteria3
- Adjuvant hormonal therapy started following complete resection of endometrial carcinoma
- Synchronous use of hormonal therapy for other indications
- Endometrial sarcoma or endometrial stroma cell sarcoma
Interventions
DRUGHormonal Antineoplastics
Hormonal therapy used for treatment in endometrial cancer patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03621904